



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C12N 5/00 ^(2006.01) **A61K 35/28** ^(2015.01)
A61K 38/18 ^(2006.01) **C12N 5/0789** ^(2010.01)
A61P 9/10 ^(2006.01)

(48) Corrigendum issued on:
25.01.2017 Bulletin 2017/04

(86) International application number:
PCT/US2010/053744

(45) Date of publication and mention
of the grant of the patent:
23.11.2016 Bulletin 2016/47

(87) International publication number:
WO 2011/050266 (28.04.2011 Gazette 2011/17)

(21) Application number: **10825743.7**

(22) Date of filing: **22.10.2010**

(54) **COMPOSITIONS AND USES FOR TREATING PROGRESSIVE MYOCARDIAL INJURY DUE TO A VASCULAR INSUFFICIENCY**

ZUSAMMENSETZUNGEN UND VERWENDUNGEN ZUR BEHANDLUNG FORTSCHREITENDER MYOKARDIALVERLETZUNGEN AUFGRUND VON GEFÄSSINSUFFIZIENZ

COMPOSITIONS ET UTILISATIONS DANS LE TRAITEMENT D'UNE LÉSION MYOCARDIQUE ÉVOLUTIVE DUE À UNE INSUFFISANCE VASCULAIRE

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(74) Representative: **Wright, Simon Mark**
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

(30) Priority: **23.10.2009 US 254539 P**

(43) Date of publication of application:
29.08.2012 Bulletin 2012/35

(56) References cited:
US-A1- 2006 019 888 US-A1- 2007 105 217
US-A1- 2007 105 217 US-A1- 2007 190 127
US-A1- 2007 190 127 US-A1- 2007 275 362
US-A1- 2007 275 362 US-A1- 2010 143 317

(60) Divisional application:
16198257.4

(73) Proprietor: **Amorcyte, Inc.**
Hackensack, NJ 07601 (US)

• **AIUTI ALESSANDRO ET AL: "Human CD34+ cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 94, no. 1, 1 July 1999 (1999-07-01), pages 62-73, XP002520079, ISSN: 0006-4971**

(72) Inventors:
• **PECORA, Andrew, L.**
Wyckoff, NJ 07481 (US)
• **PRETI, Robert, A.**
Ridgefield, CT 06877 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- KOLLET O ET AL: "Human CD34+CXCR4- sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 100, no. 8, 15 October 2002 (2002-10-15), pages 2778-2786, XP002324815, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2002-02-0564
- A. KAWAMOTO ET AL: "CD34-Positive Cells Exhibit Increased Potency and Safety for Therapeutic Neovascularization After Myocardial Infarction Compared With Total Mononuclear Cells", CIRCULATION, vol. 114, no. 20, 14 November 2006 (2006-11-14), pages 2163-2169, XP055020354, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.106.644518
- YEH E T H ET AL: "Transdifferentiation of Human Peripheral Blood CD34<+>-Enriched Cell Population Into Cardiomyocytes, Endothelial Cells, and Smooth Muscle Cells In Vivo", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 108, no. 17, 28 October 2003 (2003-10-28), pages 2070-2073, XP002433317, ISSN: 0009-7322, DOI: 10.1161/01.CIR.0000099501.52718.70
- W. WOJAKOWSKI: "Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ Stem Cells, and Mononuclear Cells Expressing Early Cardiac, Muscle, and Endothelial Markers Into Peripheral Blood in Patients With Acute Myocardial Infarction", CIRCULATION, vol. 110, no. 20, 16 November 2004 (2004-11-16), pages 3213-3220, XP055009629, ISSN: 0009-7322, DOI: 10.1161/01.CIR.0000147609.39780.02
- ZHANG ET AL: "Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, ACADEMIC PRESS, GB, vol. 44, no. 2, 16 January 2008 (2008-01-16), pages 281-292, XP022481145, ISSN: 0022-2828
- YAMAGUCHI J-I ET AL: "Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 107, no. 9, 11 March 2003 (2003-03-11), pages 1322-1328, XP002305134, ISSN: 0009-7322, DOI: 10.1161/01.CIR.0000055313.77510.22
- LIU X ET AL: "Neuregulin-1/erbB-Activation Improves Cardiac Function and Survival in Models of Ischemic, Dilated, and Viral Cardiomyopathy", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 48, no. 7, 3 October 2006 (2006-10-03), pages 1438-1447, XP028006726, ISSN: 0735-1097, DOI: 10.1016/J.JACC.2006.05.057 [retrieved on 2006-10-03]
- HILL J M ET AL: "Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 348, no. 7, 1 February 2003 (2003-02-01), pages 593-600, XP002980439, ISSN: 0028-4793, DOI: 10.1056/NEJMOA022287
- VASA M ET AL: "Number and Migratory Activity of Circulating Endothelial Progenitor Cells Inversely Correlate With Risk Factors for Coronary Artery Disease", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 89, no. 1, 6 July 2001 (2001-07-06), pages E1-E7, XP002980437, ISSN: 0009-7330
- VASA M ET AL: "Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 89, no. 1, 6 July 2001 (2001-07-06), pages E1-E7, XP002313345, ISSN: 0009-7330
- "Chapter 22" In: Braunwald: "Heart diseases 8th edition", 1 January 2008 (2008-01-01), Saunders Elsevier, Philadelphia pages 541-560,

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification